Biopharma & Life Sciences

Ventyx Biosciences Executive Compensation (FY24)

Name: Ventyx Biosciences (VTYX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

VTYX · Executive and director compensation, fiscal 2023 to 2024

Chief executive, fiscal 2024

◇

Raju Mohan

Latest say-on-pay support

June 4, 2025

Free for 3 days · no card

See how Ventyx Biosciences’s pay stands against its peers

Ventyx Biosciences's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
Peer-group intelligence, custom peer reruns and governance screens
Every other company we cover, with alerts when they file

Start my free trial on VTYX See the plan and pricing

No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.

Velarion Intel, $499/month, or $5,000/year, about two months free: one seat · every company we cover, with dashboards, peer screens and board-ready briefs.

The paid brief on Ventyx Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$500 for the Executive Compensation Report. Both reports for $900.

Get the executive brief Get the board briefNo account needed.

Data as of November 7, 2026Latest filing (8-K): June 10, 2025

3 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Ventyx Biosciences brief$500Get the executive brief

Velarion Intel, one year, every company

87 figures on this page: 85 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Ventyx Biosciences' chief executive and what were they paid?

Total compensation for Raju Mohan, Chief Executive Officer, President and Director, came to $1,283,015 in fiscal 2024. Mohan's total moved 86.4% lower from the $9,411,949 reported for fiscal 2023.

What was Ventyx Biosciences' say-on-pay result?

The say-on-pay proposal drew 64.4% of votes cast including abstentions in favor at the meeting held June 4, 2025 for fiscal 2024.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Raju Mohan Chief Executive Officer, President and Director	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Matthew Moore Chief Operating Officer	◇	—	—	◇	◇	—	◇	◇
Raju Mohan Chief Executive Officer, President and Director	◇	—	—	◇	◇	—	◇	◇
Martin Auster Former Chief Financial Officer Departed during or after this year	◇	—	—	◇	—	—	◇	◇
Mark Forman Chief Medical Officer	◇	—	—	◇	◇	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2024

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Mark Forman	OPTION	◇	—	—	◇	—	◇	◇
Matthew Moore	OPTION	◇	—	—	◇	—	◇	◇
Raju Mohan	OPTION	◇	—	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2024 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Raju Mohan	Option	◇	—	◇	12/18/2033
	Option	◇	—	◇	1/2/2034
	Option	◇	—	◇	1/17/2033
	Option	◇	—	◇	12/17/2031
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/4/2032
	Option	◇	—	◇	9/18/2031
	RSU	◇	◇	—	—
Mark Forman	Option	◇	—	◇	8/12/2034
Matthew Moore	Option	◇	—	◇	5/16/2034

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.

Fiscal 2024

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Sheila Gujrathi, M.D Board chair	◇	—	◇	—	—	—	◇
Somasundaram Subramaniam, M.B.A	◇	—	◇	—	—	—	◇
Onaiza Cadoret-Manier, M.B.A	◇	—	◇	—	—	—	◇
William White, J.D., M.P.P	◇	—	◇	—	—	—	◇
Allison Hulme, Ph.D	◇	—	◇	—	—	—	◇

Raju Mohan, Ph.D served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2024	June 4, 2025	=	◇	◇	◇
2023	June 5, 2024	=	◇	◇	◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Raju Mohan (Chief Executive Officer, President and Director), FY2024 total compensation $1,283,015 (base salary $621,920) [exec_comp, SEC accession 0000950170-25-057384, filed 2025-04-23]

See a complete sample report

What this page does not include

Everything above is a fact Ventyx Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Say-on-pay responsiveness

Ventyx Biosciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.

Responsiveness analysis

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

87 figures on this page: 85 cited to the filing that reported them, 2 calculated from figures it prints.

85 cited to the filing

2 calculated from the filing

Documents cited

8-K, filed June 10, 2025
0000950170-25-084244
DEF 14A, filed April 23, 2025
0000950170-25-057384
Director Compensation · Outstanding Equity Awards at Fiscal 2024 Year-End · Summary Compensation Table for Fiscal 2024
8-K, filed June 6, 2024
0001193125-24-156047

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Ventyx Biosciences executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/VTYX (accessed 2026).

Short form: data: Velarion

The paid brief for Ventyx Biosciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$500 for the Executive Compensation Report. Both reports for $900.

Get the executive brief Get the board briefNo account needed.

3 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/VTYX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Ventyx Biosciences executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Ventyx Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Ventyx Biosciences

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

What this page does not include

Citations

Documents cited

The paid brief for Ventyx Biosciences

Biopharma & Life Sciences rankings

Terms on this page